Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.38 |
| ▸ | LPL | P06858 | 9/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021403 | 0.92 | LIPG (0.43) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL16011151 | 0.90 | ROCK1 (0.36) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL16021406 | 0.83 | ROCK1 (0.40) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL16011263 | 0.81 | ROCK1 (0.44) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL14488072 | 0.79 | ROCK1 (0.38) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL14488670 | 0.79 | LIPG (0.38) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL19647680 | 0.78 | ROCK1 (0.40) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL13064191 | 0.78 | ROCK1 (0.40) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL780202 | 0.77 | ROCK1 (0.39) | ROCK1LIPGLPLFFAR1F11 | |
| SCHEMBL12215730 | 0.77 | LPL (0.44) | ROCK1LIPGLPLFFAR1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2726482-B1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| EP-2726482-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013004551-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | ALK, FLT1, ACVR1 | ROCK1 35/4885LIPG 172/4885LPL 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.